165 related articles for article (PubMed ID: 28121642)
1. Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival.
Odei B; Boothe D; Suneja G; Werner TL; Gaffney DK
Am J Clin Oncol; 2018 Aug; 41(8):784-791. PubMed ID: 28121642
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
3. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival.
Boothe D; Orton A; Odei B; Stoddard G; Suneja G; Poppe MM; Werner TL; Gaffney DK
Gynecol Oncol; 2016 Jun; 141(3):421-427. PubMed ID: 27005441
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
6. The Addition of Adjuvant Chemotherapy to Radiation in Early-Stage High-Risk Endometrial Cancer: Survival Outcomes and Patterns of Care.
Boothe D; Williams N; Odei B; Poppe MM; Werner TL; Suneja G; Gaffney DK
Int J Gynecol Cancer; 2017 Jun; 27(5):912-922. PubMed ID: 28498257
[TBL] [Abstract][Full Text] [Related]
7. Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis.
Wong AT; Lee YC; Schwartz D; Lee A; Shao M; Han P; Choi K; Schreiber D
Int J Gynecol Cancer; 2017 Jul; 27(6):1171-1177. PubMed ID: 28574930
[TBL] [Abstract][Full Text] [Related]
8. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
[TBL] [Abstract][Full Text] [Related]
9. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
[TBL] [Abstract][Full Text] [Related]
10. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
Matsuo K; Johnson MS; Im DD; Ross MS; Bush SH; Yunokawa M; Blake EA; Takano T; Klobocista MM; Hasegawa K; Ueda Y; Shida M; Baba T; Satoh S; Yokoyama T; Machida H; Ikeda Y; Adachi S; Miyake TM; Iwasaki K; Yanai S; Takeuchi S; Nishimura M; Nagano T; Takekuma M; Shahzad MMK; Pejovic T; Omatsu K; Kelley JL; Ueland FR; Roman LD
J Surg Oncol; 2018 Mar; 117(3):488-496. PubMed ID: 29044542
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy in uterine carcinosarcoma: Comparison of a doublet and a triplet chemotherapeutic regimen.
Maheshwari U; Rajappa SK; Talwar V; Goel V; Dash PK; Sharma M; Goyal P; Jain P; B Koyyala VP; Doval DC
Indian J Cancer; 2021; 58(2):179-184. PubMed ID: 33753600
[TBL] [Abstract][Full Text] [Related]
12. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
[TBL] [Abstract][Full Text] [Related]
13. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
14. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis.
Rauh-Hain JA; Starbuck KD; Meyer LA; Clemmer J; Schorge JO; Lu KH; Del Carmen MG
Gynecol Oncol; 2015 Oct; 139(1):84-9. PubMed ID: 26307402
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis.
Stokes WA; Robin TP; Jackson MW; Amini A; Schefter TE; Lefkowits CC; Fisher CM
Am J Clin Oncol; 2018 Oct; 41(10):927-932. PubMed ID: 28654573
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy and prognosis in uterine carcinosarcoma.
Chiang CY; Huang HJ; Chang WY; Yang LY; Wu RC; Wang CC; Tung HJ; Chao A; Lai CH
J Formos Med Assoc; 2021 Nov; 120(11):1977-1987. PubMed ID: 33992491
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis.
Gockley AA; Rauh-Hain JA; Anders AM; Meyer LA; Clemmer J; Lu KH; Clark RM; Schorge JO; del Carmen MG
Int J Gynecol Cancer; 2016 May; 26(4):697-704. PubMed ID: 26825834
[TBL] [Abstract][Full Text] [Related]
19. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
[TBL] [Abstract][Full Text] [Related]
20. Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
Seagle BL; Dayno M; Strohl AE; Graves S; Nieves-Neira W; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):472-478. PubMed ID: 27760707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
